Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma
Authors:
- 8 March 2021
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (8) , 1995-1999
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 TrialCancers, 2020
- From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK+British Journal of Haematology, 2019
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Paediatric non‐Hodgkin lymphoma ‐ perspectives in translational biologyBritish Journal of Haematology, 2016
- Anaplastic large cell lymphoma in paediatric and young adult patientsBritish Journal of Haematology, 2016
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosisLeukemia, 2012
- Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 StudyJournal of Clinical Oncology, 2011
- Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase–positive anaplastic large cell lymphoma with tumor dissemination and relapse riskBlood, 2010
- Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL GroupJournal of Clinical Oncology, 2009
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994